About Sana Biotechnology, Inc.
https://www.sana.comSana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others.
CEO
Steven D. Harr
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 107
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Wedbush
Outperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FMR LLC
Shares:37.43M
Value:$177.42M
FLAGSHIP PIONEERING INC.
Shares:25M
Value:$118.51M
BAILLIE GIFFORD & CO
Shares:11.44M
Value:$54.21M
Summary
Showing Top 3 of 196
About Sana Biotechnology, Inc.
https://www.sana.comSana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $43.52M ▼ | $-42.15M ▲ | 0% | $-0.16 ▲ | $-38.96M ▲ |
| Q2-2025 | $0 | $94.97M ▲ | $-93.8M ▼ | 0% | $-0.39 ▼ | $-47.51M ▼ |
| Q1-2025 | $0 | $50.63M ▼ | $-49.39M ▼ | 0% | $-0.21 | $-46.98M ▼ |
| Q4-2024 | $0 | $50.87M ▼ | $-49.07M ▲ | 0% | $-0.21 ▲ | $-45.17M ▲ |
| Q3-2024 | $0 | $61.76M | $-59.92M | 0% | $-0.25 | $-57.7M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $153.05M ▲ | $435.43M ▲ | $240.12M ▲ | $195.31M ▲ |
| Q2-2025 | $72.67M ▼ | $361.64M ▼ | $239.09M ▲ | $122.56M ▼ |
| Q1-2025 | $104.7M ▼ | $445.47M ▼ | $236.39M ▼ | $209.08M ▼ |
| Q4-2024 | $152.5M ▼ | $501.02M ▼ | $250.52M ▼ | $250.5M ▼ |
| Q3-2024 | $199.01M | $559.39M | $266.91M | $292.48M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-42.15M ▲ | $-29.43M ▲ | $-48.02M ▼ | $109.54M ▲ | $32.09M ▲ | $-29.47M ▲ |
| Q2-2025 | $-93.8M ▼ | $-33.1M ▲ | $7.68M ▼ | $561K ▼ | $-24.86M ▲ | $-32.99M ▲ |
| Q1-2025 | $-49.39M ▼ | $-48.66M ▼ | $16.6M ▼ | $982K ▲ | $-31.07M ▼ | $-48.79M ▼ |
| Q4-2024 | $-49.07M ▲ | $-47.16M ▲ | $47.09M ▲ | $643K ▼ | $570K ▲ | $-47.6M ▲ |
| Q3-2024 | $-59.92M | $-51.82M | $41.77M | $2.08M | $-7.96M | $-55.91M |
CEO
Steven D. Harr
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 107
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Wedbush
Outperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FMR LLC
Shares:37.43M
Value:$177.42M
FLAGSHIP PIONEERING INC.
Shares:25M
Value:$118.51M
BAILLIE GIFFORD & CO
Shares:11.44M
Value:$54.21M
Summary
Showing Top 3 of 196